Riboway Therapeutics
June 18, 2025
Start-Up Stadium
Platform for Therapeutics
North Lobby
Riboway Therapeutics is pioneering RNA-targeted therapeutics using an AI-driven platform that decodes RNA regulation to precisely control protein expression—upregulation, downregulation, activation, or inhibition. We’re the first to activate undruggable proteins via RNA-targeting, opening new treatment paths for diseases with no cures. Our lead program targets the root cause of a monogenic neurodegenerative disease, with a development candidate aiming for clinical PoC in three years. With successful validation across 5/5 targets, we’re unlocking the next generation of RNA medicines.
Company HQ City:
Cambridge
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2024
CEO
Avery Yan
Website
https://riboway.com/
Primary Speaker
)
)
){kind=logo}
){kind=logo}
){kind=logo}